Cannabidiol 1 is under clinical development by STERO Biotechs and currently in Phase II for Crohn’s Disease (Regional Enteritis). According to GlobalData, Phase II drugs for Crohn’s Disease (Regional Enteritis) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cannabidiol 1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cannabidiol 1 overview
Cannabidiol is under development for the treatment of steroid-dependent Crohn’s disease. The drug candidate acts by targeting cannabinoid receptor 1(CNR1) and cannabinoid receptor 2 (CNR2). The therapeutic candidate is a synthetic form of cannabidiol.
STERO Biotechs overview
STERO Biotechs is a clinical-stage company for the research and development of novel Cannabidiol (CBD) based treatments and solutions that will potentially benefit millions of patients by reducing the side effects and the need of steroid therapy. STERO Biotechs is headquartered in Bnei Brak, Israel.
For a complete picture of Cannabidiol 1’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
